Principle Labs LLC

Principle Labs LLC was paid $46.31M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 40% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Pennsylvania

Rank by total paid#6 of 95

Median peer was paid$153K

This provider vs. median303×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	59,634	$3.66M
2019	61,421	$4.02M
2020	81,721	$6.03M
2021	96,042	$7.92M
2022	125,154	$9.76M
2023	117,715	$7.41M
2024incomplete	122,826	$7.52M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	40%	150,169	95,940	$18.47M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	26%	145,744	86,053	$11.99M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	23%	237,735	122,638	$10.70M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	3.2%	15,242	10,811	$1.46M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.8%	7,292	4,915	$815K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	1.4%	8,511	6,506	$645K
87150		1.2%	2,846	2,027	$558K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.1%	3,244	2,271	$487K
87481		<1%	6,661	4,779	$167K
87653		<1%	6,533	4,670	$76K
87640		<1%	6,602	4,725	$75K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	5,411	3,899	$74K

92 more codes

87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	4,087	$70K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	4,081	$54K
87641		<1%	4,686	$46K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	5,424	$46K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	2,236	$44K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	3,149	$39K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	2,007	$36K
87500		<1%	3,573	$31K
82172		<1%	2,472	$30K
81226		<1%	104	$28K
87529		<1%	1,037	$27K
80061	Lipid panel	<1%	2,661	$24K
82670		<1%	1,162	$22K
82607		<1%	1,905	$20K
82747		<1%	1,567	$19K
84481		<1%	1,659	$19K
80050	General health panel	<1%	1,605	$18K
84146		<1%	1,363	$18K
81225		<1%	101	$18K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,434	$15K
82728		<1%	1,469	$14K
87563		<1%	2,916	$12K
84153		<1%	877	$11K
80053	Comprehensive metabolic panel	<1%	1,757	$11K
87625		<1%	700	$11K
81227		<1%	82	$11K
84443	Thyroid stimulating hormone (TSH)	<1%	1,035	$11K
84439		<1%	1,730	$10K
83002		<1%	639	$8K
83970		<1%	196	$8K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	982	$6K
86803		<1%	486	$5K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	349	$5K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	923	$4K
87631		<1%	350	$4K
85027		<1%	964	$4K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	401	$3K
82533		<1%	203	$3K
87340		<1%	434	$3K
86769		<1%	81	$3K
84403		<1%	147	$2K
87471		<1%	348	$2K
86706		<1%	273	$2K
86708		<1%	204	$2K
86709		<1%	354	$2K
87511		<1%	136	$1K
84144		<1%	91	$1K
83001		<1%	92	$1K
86480		<1%	121	$760.35
83550		<1%	110	$661.51
86705		<1%	145	$527.25
83540		<1%	99	$497.43
82977		<1%	100	$483.48
84480		<1%	247	$473.96
82150		<1%	89	$416.00
84100		<1%	126	$375.56
84436		<1%	360	$323.29
80074		<1%	28	$245.05
86703		<1%	55	$238.07
87561		<1%	101	$200.95
82043		<1%	44	$192.56
81003		<1%	337	$185.58
86780		<1%	51	$120.80
87493		<1%	77	$118.38
36415	Collection of venous blood by venipuncture	<1%	51	$91.56
80178		<1%	89	$79.17
86704		<1%	30	$74.52
80076		<1%	43	$74.08
86707		<1%	30	$71.51
87350		<1%	30	$71.26
84466		<1%	27	$70.16
82947		<1%	71	$33.97
80048	Basic metabolic panel (calcium, ionized)	<1%	48	$33.20
85045		<1%	27	$21.96
84155		<1%	34	$13.02
82040		<1%	33	$12.71
86592		<1%	12	$12.00
84478		<1%	36	$11.28
84460		<1%	17	$9.36
84450		<1%	17	$9.14
84075		<1%	18	$9.14
82247		<1%	17	$8.94
82565		<1%	40	$8.65
82465		<1%	35	$8.54
81002		<1%	76	$8.32
82436		<1%	16	$4.60
82310		<1%	16	$4.13
82374		<1%	16	$3.90
84295		<1%	16	$3.85
84132		<1%	16	$3.81
81001		<1%	15	$1.20
84479		0%	25	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPOLETE, JASON (COO)